A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

Inclusion Criteria:

- Eastern Cooperative Oncology Group performance status 0 or 1

- Histologically confirmed diagnosis of locally advanced, recurrent, and/or metastatic
triple-negative breast cancer, ovarian cancer, gastric cancer, colorectal cancer,
pancreatic cancer, melanoma, or mesothelioma

- Radiologically measurable and clinically evaluable disease as per RECIST v1.1

- Life expectancy of greater than or equal to (>/=) 16 weeks

- Ability to comply with the collection of tumor biopsies; tumors accessible for biopsy

- Adequate bone marrow, liver, cardiac, and renal function

Exclusion Criteria:

- Allergy or hypersensitivity to components of either study drug formulation

- Active or untreated central nervous system (CNS) metastases as determined by computed
tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or
prior radiographic assessments. Participants with radiographically stable,
asymptomatic, previously irradiated lesions are eligible provided participant is >/=4
weeks beyond completion of cranial irradiation and >/=3 weeks off of corticosteroid
therapy

- Participants with leptomeningeal disease; metastases to the brain stem, midbrain,
pons, medulla, or within 10 millimeters (mm) of the optic apparatus (optic nerves and
chiasm)

- History of human immunodeficiency virus (HIV)

- Participants with active hepatitis B, active hepatitis C, or active tuberculosis

- Pregnant or lactating women